Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.

@article{Frustaci1997Increasing4A,
  title={Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.},
  author={Sergio Frustaci and Angela Buonadonna and Enzo Galligioni and Donata Favaro and Antonino De Paoli and Giovanni Lo Re and Roberto Sorio and Salvatore Tumolo and Silvio Monfardini},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 4},
  pages={1418-26}
}
PURPOSE To determine the maximum-tolerated dose (MTD) of 4'-epidoxorubicin (EPI) in combination with full dose of ifosfamide (IFO) when granulocyte-macrophage colony-stimulating factor (GM-CSF) was used, to estimate its clinical efficacy, and to evaluate the mobilization of hematopoietic progenitors. PATIENTS AND METHODS Previously untreated advanced patients were treated with fixed doses of IFO at 1.8 g/m2/d for 5 days and escalating doses of EPI. The starting dose level of EPI was 50 mg/m2… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

A malignant peripheral nerve-sheath tumour responding to chemotherapy.

The Journal of bone and joint surgery. British volume • 2004

Similar Papers

Loading similar papers…